Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
Non-small-cell lung adenocarcinoma cancer exhibits higher resistance to chemotherapy than small cell lung cancer, which requires novel strategies. To further understand underlying mechanisms for non-small-cell lung adenocarcinoma cancer cell proliferation, we explored the role of Meis1 in non-small-...
To determine the pharmacodynamic mechanism underlying Cordyceps sinensis relief in a murine model of non-small cell lung cancer (NSCLC). We created a murine model of NSCLC and studied the potential molecular mechanism by which C. sinensis relieved NSCLC
Immune checkpoint inhibitors (ICIs) have ushered in a remarkable advancement in the management of advanced non-small-cell lung cancer (NSCLC)1. Nevertheless, only 15–30% of patients will have long-lasting benefits2. Identifying resistance mechanisms of ICIs and predicting treatment efficacy are impe...
This cohort study evaluates trends in survival after immune checkpoint inhibitor therapy in patients with advanced non–small cell lung cancer by age.
Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset Data in Brief, Volume 37, August 2021, Pages 107195 David Waterhouse, Jenny Lam, Keith A. Betts, Lei Yin, Sophie Gao, Yong Yuan, John Hartman,...
Non-Small Cell Carcinoma of the Lung Non-small cell lung cancer Non-small cell lung cancer Non-Small Cell Lung Cancer Collaborative Group Non-Small Cell Lung Carcinoma Non-Small-Cell Bronchogenic Carcinoma Non-Smart Card Mobility NON-SME
Non-small cell lung cancer ORR: Objective response rate OS: Overall survival PD: Progressive disease PD-1: Programmed cell death protein-1 PD-L1: Programmed death-ligand 1 PFS: Progression-free survival PR: Partial response RECIST v1.1: Response Evaluation Criteria in Solid Tumors ve...
Non-small cell lung cancer (NSCLC) is one of the most threatening malignancies to human health and life. In most cases, patients with NSCLC are already at an advanced stage when they are diagnosed. In recent years, lung cancer has made great progress in precision therapy, but the efficacy ...
This study focused on a novel strategy that combines deep learning and radiomics to predict epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC) using computed tomography (CT). A total of 1280 patients wit